US2018228743A1PendingUtilityA1
Compounds and methods of promoting myelination
Est. expiryJul 27, 2036(~10 yrs left)· nominal 20-yr term from priority
A61P 25/14A61K 31/137A61K 31/7105A61K 31/4545A61K 38/16A61K 31/4535A61K 31/496A61K 31/198A61K 45/06A61K 38/215A61K 39/3955A61K 31/136A61K 31/5375A61K 31/138A61P 25/28A61K 31/4196A61K 31/4174A61P 25/18A61P 25/16A61K 31/7088A61P 25/00C12N 15/1137C12N 9/50
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method of promoting the generation of oligodendrocytes from oligodendrocyte precursor cells by enhancing their survival and/or maturation includes administering to the cell an effective amount of an agent that enhances and/or induces accumulation of Δ8,9-unsaturated sterol intermediates of the cholesterol biosynthesis pathway in the oligodendrocyte precursor cells.
Claims
exact text as granted — not AI-modified1 - 58 . (canceled)
59 . A method of enhancing the generation of oligodendrocytes in a subject in need thereof, the method comprising administering an effective amount of Cis-N-cyclohexyl-N-ethyl-3-(3-chloro-4-cyclohexylphenyl)prop-2-enylamine or a pharmaceutically acceptable salt thereof to the subject.
60 . The method of claim 59 , wherein the method is a method of treating a subject with a myelin related disorder, comprising administering an effective amount of Cis-N-cyclohexyl-N-ethyl-3-(3-chloro-4-cyclohexylphenyl)prop-2-enylamine or a pharmaceutically acceptable salt thereof to the subject.
61 . The method of claim 60 , wherein the myelin related disorder is multiple sclerosis.
62 . The method of claim 61 , further comprising the step of co-administering to the subject an effective amount of interferon beta-la, interferon beta-lb, natalizumab, natalizumab, glatiramer acetate, mitoxantrone, L-dopa, a cholinesterase inhibitor, an anticholinergic, a dopamine agonist or a steroid.Join the waitlist — get patent alerts
Track US2018228743A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.